CD44 and colorectal carcinoma: In addition, we have also observed a significant increase in the expression of CD44 and CD133 in CRC tumour cells with acquired resistance to anti-EGFR mAb and TKI therapies further highlighting the role played by CSCs not only in primary drug resistance, but also in the development of acquired drug resistance.